Edgewise Therapeutics (NASDAQ:EWTX) Research Coverage Started at HC Wainwright

HC Wainwright began coverage on shares of Edgewise Therapeutics (NASDAQ:EWTX) in a report released on Monday morning, Marketbeat.com reports. The brokerage issued a buy rating and a $42.00 target price on the stock. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.45) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.75) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.93) EPS, FY2028 earnings at ($0.97) EPS and FY2029 earnings at $3.10 EPS.

Several other research analysts also recently commented on the company. Scotiabank downgraded Edgewise Therapeutics from a “sector outperform” rating to a “sector perform” rating and decreased their price objective for the stock from $50.00 to $14.00 in a research note on Wednesday, April 2nd. Royal Bank Of Canada restated an “outperform” rating and set a $48.00 target price on shares of Edgewise Therapeutics in a research note on Thursday, June 5th. Wedbush reiterated an “outperform” rating and issued a $43.00 price target on shares of Edgewise Therapeutics in a research report on Monday, April 21st. Piper Sandler reissued an “overweight” rating and issued a $51.00 price objective on shares of Edgewise Therapeutics in a research note on Wednesday, April 2nd. Finally, Guggenheim assumed coverage on shares of Edgewise Therapeutics in a research note on Wednesday, April 30th. They set a “buy” rating and a $41.00 target price on the stock. Two equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $40.00.

Edgewise Therapeutics Stock Up 1.5%

Shares of Edgewise Therapeutics stock opened at $13.01 on Monday. The company has a market cap of $1.37 billion, a PE ratio of -8.39 and a beta of 0.25. The business has a 50 day moving average of $14.71 and a 200 day moving average of $20.82. Edgewise Therapeutics has a 52 week low of $10.60 and a 52 week high of $38.12.

Edgewise Therapeutics (NASDAQ:EWTX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.43) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.02. On average, research analysts anticipate that Edgewise Therapeutics will post -1.45 earnings per share for the current year.

Insider Buying and Selling

In other Edgewise Therapeutics news, CEO Kevin Koch sold 4,276 shares of the business’s stock in a transaction dated Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $70,340.20. Following the transaction, the chief executive officer directly owned 20,619 shares in the company, valued at $339,182.55. The trade was a 17.18% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel John R. Moore sold 1,930 shares of the business’s stock in a transaction that occurred on Friday, May 2nd. The shares were sold at an average price of $16.45, for a total value of $31,748.50. Following the completion of the sale, the general counsel directly owned 6,531 shares in the company, valued at approximately $107,434.95. The trade was a 22.81% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 14,258 shares of company stock valued at $234,544 over the last ninety days. 23.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Edgewise Therapeutics

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. boosted its position in shares of Edgewise Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,594 shares of the company’s stock worth $203,000 after acquiring an additional 482 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its position in shares of Edgewise Therapeutics by 55.6% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 3,194 shares of the company’s stock worth $70,000 after acquiring an additional 1,141 shares in the last quarter. Alliancebernstein L.P. lifted its stake in Edgewise Therapeutics by 1.7% during the fourth quarter. Alliancebernstein L.P. now owns 77,260 shares of the company’s stock worth $2,063,000 after purchasing an additional 1,300 shares during the last quarter. Arizona State Retirement System boosted its holdings in Edgewise Therapeutics by 12.3% in the first quarter. Arizona State Retirement System now owns 12,201 shares of the company’s stock valued at $268,000 after purchasing an additional 1,338 shares in the last quarter. Finally, Diadema Partners LP acquired a new position in Edgewise Therapeutics in the fourth quarter valued at approximately $36,000.

About Edgewise Therapeutics

Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.